Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin's disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Pathology

• Publication date

  2002-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/path.1151PMID 12210089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiogenesis spectrum in the stroma of B‐cell non‐Hodgkin's lymphomas. An immunohistochemical and ultrastructural study

  2009cited by this paper
• Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.

  2001cited by this paper
• Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs)

  2000cited by this paper
• Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

  1999cited by this paper
• Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease

  1999cited by this paper
• Expression of VEGF in routinely fixed material using a new monoclonal

  1998influential reference
• Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

  1998cited by this paper
• In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.

  1998cited by this paper
• Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.

  1998cited by this paper
• Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.

  1997cited by this paper
• Expression of vascular endothelial growth factor in lymphomas and castleman's disease

  1997cited by this paper
• A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.

  1997cited by this paper
• Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.

  1997cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.

  1996cited by this paper
• Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor.

  1996cited by this paper
• Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.

  1995cited by this paper
• Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma.

  1995cited by this paper
• Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

  1995cited by this paper
• Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

  1995cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

  1995cited by this paper
• Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines.

  1994cited by this paper
• Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis

  1994cited by this paper
• Relation of neovascularisation to metastasis of non-small-cell lung cancer.

  1992cited by this paper
• Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

  1992cited by this paper
• Microvessel quantitation and prognosis in invasive breast carcinoma.

  1992cited by this paper
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

  1992cited by this paper
• Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

  1992cited by this paper
• Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells.

  1991cited by this paper
• Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

  1991cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype.

  1990cited by this paper
• Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration

  1990cited by this paper
• JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections.

  1990cited by this paper
• Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

  1984cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Mechanism of the induction of angiogenesis by human neoplastic lymphoid tissue: Studies on the chorioallantoic membrane (CAM) of the chick embryo

  1980cited by this paper
• Method for the Quantitative Morphologic Analysis of Tissues

  1943cited by this paper

• Endothelial Cells in Lymphomas

  2025cites this paper
• The Tumor Microenvironment Remodeled by Epstein-Barr Virus: From Primary Site to Distant Metastatic Niche.

  2025cites this paper
• Metabolic regulation of the tumour and its microenvironment: The role of Epstein–Barr virus

  2024cites this paper
• Paraneoplastic Syndromes in Hodgkin’s Lymphoma

  2024cites this paper
• Clinical relevance of cyclooxygenase 2 and vascular endothelial growth factor-A expression in classical Hodgkin lymphoma

  2023cites this paper
• Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution

  2023cites this paper
• Vascular Growth in Lymphomas: Angiogenesis and Alternative Ways

  2023cites this paper
• Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence

  2021cites this paper
• Prognostic Importance of Thrombospondin-1, VEGF, PDGFR- β in Diffuse Large B-Cell Lymphoma Cases

  2021cites this paper
• Assessment of endothelial progenitor cells, VEGF-A and SDF-1α in Hodgkin's lymphoma

  2021cites this paper
• Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

  2021influential citation
• Epstein‐Barr virus latent membrane protein‐1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy

  2021cites this paper
• Angiogenesis Imaging Study Using [18F] RGD-K5 PET/CT in Patients with Lymphoma Under Chemotherapy.

  2020cites this paper
• Hematologic malignancies

  2020cites this paper
• Association of VEGFA gene polymorphisms with susceptibility to non-Hodgkin's lymphoma: Evidences from population-based and in silico studies

  2020cites this paper
• Kidney disease in lymphoma

  2020cites this paper
• How Epstein-Barr Virus “Manipulates” The Tumoral Microenvironment in Hodgkin Lymphoma?

  2019cites this paper
• Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition

  2019cites this paper
• Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It

  2019cites this paper
• Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia

  2019cites this paper
• Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.

  2019cites this paper
• The Microenvironment in Epstein–Barr Virus-Associated Malignancies

  2018cites this paper
• Precision Molecular Pathology of Hodgkin Lymphoma

  2018cites this paper
• Hodgkin lymphoma secreted factors determine macrophage polarization and function

  2018cites this paper
• Role of EBV in Classical Hodgkin Lymphoma

  2018cites this paper
• Differential vascular endothelial growth factor expression in neoplastic and non-neoplastic components of classic Hodgkin’s lymphoma

  2017cites this paper
• Atypical variants of nodular lymphocyte-predominant Hodgkin lymphoma show low microvessel density and vessels of distention type.

  2017cites this paper
• The hypoxia signalling pathway in haematological malignancies

  2017cites this paper
• Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma

  2017cites this paper
• Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

  2017cites this paper
• Mechanisms underlying the association between obesity and Hodgkin lymphoma

  2016cites this paper
• Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene

  2016cites this paper
• Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.

  2016cites this paper
• Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs—syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin’s lymphoma

  2016cites this paper
• Hodgkin Lymphoma of the Hepatobiliary Tract

  2016cites this paper
• WNT signalling affects cell migration, invasion and the lymphoma-endothelial interplay in Hodgkin Lymphoma

  2016cites this paper
• Lymphoma: Immune Evasion Strategies

  2015cites this paper
• Focal segmental glomerulosclerosis in a patient with mantle cell lymphoma

  2015cites this paper
• Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine

  2015cites this paper
• Role of vascular endothelial growth factor C in classical Hodgkin lymphoma

  2015cites this paper
• Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma

  2014cites this paper
• Insights in Hodgkin Lymphoma angiogenesis.

  2014cites this paper
• Chapter 14 – Paraneoplastic Glomerulopathy

  2014cites this paper
• Nephrotic syndrome related to chronic neutrophilic leukemia.

  2014cites this paper
• CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma

  2014cites this paper
• Kidney involvement in leukemia and lymphoma.

  2014cites this paper
• therapeutic potential From Hodgkin's disease to Hodgkin lymphoma: biological insights and

  2013cites this paper
• human lymphoma xenografts in vivo Targeting autocrine and paracrine VEGF receptor pathways inhibits

  2013cites this paper
• Radiation Enhances the Invasiveness of Irradiated and Nonirradiated Bystander Hepatoma Cells Through a VEGF-MMP2 Pathway Initiated by p53

  2013cites this paper
• The role of angiogenesis in human non-Hodgkin lymphomas.

  2013cites this paper
• Prognostic Significance of COX-2 Expression and Correlation With Bcl-2 and VEGF Expression, Microvessel Density, and Clinical Variables in Classical Hodgkin Lymphoma

  2013cites this paper
• Monoclonal antibody therapy for classical Hodgkin lymphoma

  2013cites this paper
• Serum concentrations of proangiogenic cytokines (VEGF, bFGF) depending on the histopathological types of Hodgkin lymphoma in children – preliminary report

  2012cites this paper
• Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b+/F4/80+ myeloid cell recruitment

  2012cites this paper
• mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma.

  2012cites this paper
• Targeting the vascular endothelial growth factor in hematologic malignancies

  2012cites this paper
• VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma

  2012cites this paper
• Hypoxia-inducible factors and sphingosine 1-phosphate signaling.

  2011cites this paper
• Microvessel Density Is Associated with VEGF and α-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas

  2011cites this paper
• Antiangiogenic therapies in non-Hodgkin's lymphoma.

  2011cites this paper
• Dominant expression of survival signals of endoplasmic reticulum stress response in Hodgkin lymphoma

  2011cites this paper
• Targetable molecular pathways in classical Hodgkin's lymphoma

  2011cites this paper
• Emerging drugs for Hodgkin's lymphoma

  2010cites this paper
• Tumor cell survival strategies in Hodgkin lymphoma

  2010cites this paper
• DOES SERUM SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS HAVE DIFFERENT IMPORTANCE IN PEDIATRIC ACUTE LEUKEMIA AND MALIGNANT LYMPHOMA PATIENTS?

  2010cites this paper
• Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

  2010cites this paper
• Hematopathology in Oncology

  2010cites this paper
• Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma

  2010cites this paper
• Le traitement du lymphome de Hodgkin chez l'adulte

  2010cites this paper
• Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma.

  2009cites this paper
• PLASMA HEPARANASE AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE IN CHILDREN WITH HODGKIN LYMPHOMA: Pilot Study

  2009cites this paper
• Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma

  2009cites this paper
• Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

  2009cites this paper
• Primary cutaneous diffuse large B-cell lymphoma, leg type, with expression of both vascular endothelial growth factor and its receptors.

  2009cites this paper
• Phosphorylated VEGFR2/KDR receptors are widely expressed in B‐cell non‐Hodgkin's lymphomas and correlate with hypoxia inducible factor activation

  2008cites this paper
• Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.

  2008cites this paper
• SERUM VEGF AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE IN HODGKIN LYMPHOMA

  2007cites this paper
• Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

  2007cites this paper
• The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma.

  2007cites this paper
• Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.

  2007cites this paper
• Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed–Sternberg cell

  2007cites this paper
• Serum VEGF and bFGF levels in patients with Hodgkin's lymphoma

  2007cites this paper
• Expression of vascular endothelial growth factor and its receptors in canine lymphoma.

  2007cites this paper
• Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL)

  2006influential citation
• Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma

  2006cites this paper
• Expression of cyclooxygenase-2 in Hodgkin's lymphoma:its role in cell proliferation and angiogenesis

  2006cites this paper
• A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

  2006cites this paper
• The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma

  2006cites this paper
• Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis.

  2006cites this paper
• Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies

  2006cites this paper
• Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications

  2005cites this paper
• Angiogenesis and mast cells in Hodgkin lymphoma

  2005cites this paper
• From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.

  2005cites this paper
• Angiogenesis in lymphoma: a short review.

  2005cites this paper
• From Hodgkin's Disease to Hodgkin Lymphoma: Biological Insights and Therapeutic Potential

  2005cites this paper
• Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF‐A and VEGF‐C

  2005cites this paper
• Experimentelle Therapie des Hodgkin-Lymphoms

  2005cites this paper
• Angiogenesis and tumor development

  2004cites this paper
• Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining

  2004cites this paper
• The role of hypoxia signalling pathways in tumour biology.

  2004cites this paper